<DOC>
	<DOCNO>NCT02562755</DOCNO>
	<brief_summary>This randomized Phase 3 study determine whether treatment vaccinia virus base immunotherapy ( Pexa-Vec ) follow sorafenib increase survival compare treatment sorafenib patient advance hepatocellular carcinoma receive prior systemic therapy .</brief_summary>
	<brief_title>Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib v Sorafenib Alone</brief_title>
	<detailed_description>This multi-center , randomize , open-label , Phase 3 study compare Pexa Vec follow sorafenib versus sorafenib patient advance HCC without prior systemic therapy . A total 600 patient randomly assign 2 treatment arm 1:1 ratio ( 300 arm ) reach least 570 evaluable patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histological/cytological diagnosis primary HCC Advanced stage HCC ( Barcelona Clinic Liver Cancer [ BCLC ] Stage C B per American Association Study Liver Disease [ AASLD ] guideline ) At least one measurable viable tumor liver , â‰¥1 cm long diameter ( LD ) , use dynamic imaging technique ( arterial phase triphasic computerized tomography [ CT ] scan , dynamic contrastenhanced magnetic resonance image [ MRI ] ) , injectable imagingguidance ( CT and/or ultrasound ) ChildPugh Class A Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale Adequate hematological , hepatic , renal function : Additional inclusion criterion exist Histological diagnosis cholangiocarcinoma , hepatocholangiocarcinoma , fibrolamellar carcinoma hepatoblastoma Symptomatic cardiovascular disease , include limited significant coronary artery disease ( e.g. , require angioplasty stenting ) congestive heart failure within precede 12 month Current past history cardiovascular disease ( e.g.. past history myocardial infarction , ischemic cardiomyopathy ) unless cardiology consultation clearance obtain study participation History moderate severe ascites , bleed esophageal varix , hepatic encephalopathy pleural effusion relate liver insufficiency within 6 month screen Bulky disease patient tumor encompass &gt; 50 % liver volume / inferior vena cava invasion Known significant immunodeficiency due underlie illness ( e.g. , HIV/AIDS ) and/or immunesuppressive medication include highdose corticosteroid Ongoing severe inflammatory skin condition ( determined Investigator ) require medical treatment History severe eczema ( determined Investigator ) require medical treatment Additional exclusion criterion exist</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Hepatocellular Carcinoma ( HCC )</keyword>
	<keyword>Pexastimogene Devacirepvec ( Pexa-Vec )</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>GM-CSF therapy</keyword>
	<keyword>Thymidine Kinase-Deactivated Vaccinia Virus</keyword>
	<keyword>Oncology</keyword>
	<keyword>Recombinant Vaccinia Virus</keyword>
	<keyword>Oncolytic Virus Therapy</keyword>
	<keyword>Oncolytic virotherapy</keyword>
</DOC>